US Stock MarketDetailed Quotes

ALLO Allogene Therapeutics

Watchlist
  • 1.570
  • +0.020+1.29%
Close Apr 28 16:00 ET
  • 1.571
  • +0.001+0.06%
Post 20:01 ET
341.11MMarket Cap-1.19P/E (TTM)

About Allogene Therapeutics Company

Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, David M. Tanen, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA.

Company Profile

SymbolALLO
Company NameAllogene Therapeutics
Listing DateOct 11, 2018
Issue Price18.00
Founded2017
CEODr. David D. Chang, M.D.,PhD
MarketNASDAQ
Employees229
Fiscal Year Ends12-31
Address210 East Grand Avenue
CitySouth San Francisco
ProvinceCalifornia
CountryUnited States of America
Zip Code94080-4811
Phone1-650-457-2700

Company Executives

  • Name
  • Position
  • Salary
  • Dr. David D. Chang, M.D.,PhD
  • Director, Chief Executive Officer and President
  • 14.06M
  • Geoffrey M. Parker
  • Executive Vice President and Chief Financial Officer
  • --
  • Benjamin Machinas Beneski
  • Senior Vice President and Chief Technical Officer
  • --
  • Dr. Zachary Roberts, M.D.,PhD
  • Executive Vice President, Research and Development and Chief Medical Officer
  • 8.13M
  • Annie Yoshiyama
  • Principal Accounting Officer, Senior Vice President and Corporate Controller
  • --
  • Earl Douglas
  • Senior Vice President, General Counsel, Compliance Officer and Corporate Secretary
  • --
  • Dr. Arie S. Belldegrun, F.A.C.S.,M.D.
  • Executive Chairman of the Board
  • 9.36M
  • Joshua A. Kazam
  • Director
  • 684.49K
  • David Bonderman
  • Lead Independent Director
  • --
  • Elizabeth Barrett
  • Independent Director
  • 476.43K
  • Deborah M. Messemer
  • Independent Director
  • 495.00K
  • Todd B. Sisitsky
  • Independent Director
  • --
  • John DeYoung
  • Independent Director
  • --
  • Dr. Vicki L. Sato, PhD
  • Independent Director
  • 478.79K
  • Dr. Stephen L. Mayo, PhD
  • Independent Director
  • 463.99K
  • Dr. Owen N. Witte, M.D.
  • Independent Director
  • 510.00K
  • Dr. Franz Bernard Humer, PhD
  • Independent Director
  • 585.00K

Market Insights

Donald Trump Donald Trump

Trump-Election Stocks refer to securities closely associated with business dealings, political actions, or events related to Donald Trump. Trump-Election Stocks refer to securities closely associated with business dealings, political actions, or events related to Donald Trump.

Unlock Now

Discussing

關稅風暴暫離高壓區!市場能否迎來反彈?
當地時間4月22日,美國總統特朗普公開承認美國目前對中國出口商品的關稅過高,預計稅率將大幅降低;美國財政部長貝森特也表示中美雙方關稅戰將很快降溫。4月25日,特朗普表示將爲不同國家設定「公平的」關稅稅率。特朗普此次對華關稅態度的轉變,能否平息市場恐慌情緒?關稅拉鋸戰最終結局如何? Show More

focus on technology stocks

Top tech company strong as always.